Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein (Native)

Vascular Endothelial Growth Factor A ( VEGF 165 ) Protein Datasheet

VEGF / VEGFA / VEGF165 Protein Product Information

• Synonym: VEGF165
• Protein Construction: A DNA sequence encoding the human VEGF165 isoform (P15692-4) (Met1-Arg191) was expressed. Human and Cynomolgus VEGF165 sequences are identical.
• Source: Human
• Expression Host: Human Cells

VEGF / VEGFA / VEGF165 Protein QC Testing

• Purity: > 95 % as determined by SDS-PAGE
• Bio-activity: Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC).
  The ED₅₀ for this effect is typically 1-6 ng/mL.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Ala 27
• Molecular Mass: The recombinant human VEGF165 consists of 165 amino acids and predicts a molecular mass of 19.2 KDa. It migrates as an approximately 20 and 22 KDa band in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile 100 mM Glycine, 10 mM NaCl, pH 7.0.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: VEGF / VEGFA / VEGF165 protein

VEGF / VEGFA / VEGF165 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

VEGF / VEGFA / VEGF165 Protein Description

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. As its name implies, VEGF-A activity has been mostly studied on cells of the vascular endothelium, although it does have effects on a number of other cell types (stimulation monocyte/macrophage, neurons, cancer cells, kidney epithelial cells ). VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor. Alternatively spliced transcript variants of VEGF-A, encoding either secreted or cell-associated isoforms, have been identified. Alternatively spliced isoforms of 121,145,165,183,189 and 206 amino acids in length are expressed in humans. VEGF165 appears to be the most abundant and potent isoform and is a heparin-binding growth factor with mitogenic activity for vascular endothelial cells. Human VEGF165 shares 88%, 96%, 95% and 93% aa sequence identity with mouse, porcine, canine and feline VEGF165, respectively.

References

1. Mattei MG. et al., 1996, Genomics. 32 (1):168-9.
2. Borgatti P. et al.,1998, Eur J Immunol. 27 (11): 2805-11.
3. Gengrinovitch S. et al., 1999, J Biol Chem. 274 (16): 10816-22.
4. Zachary I. et al., 2001, Cardiovasc. Res. 49: 568-81.
5. Robinson CJ. et al., 2001, J Cell Sci. 114: 853-65.
6. Lee P. et al., 2002, Proc Natl Acad Sci. 99: 10470-5.
7. Lee GY. et al., 2006, Protein expressed and Purification. 46: 503-9.